ASCO's TAPUR Study: Off-Label Drugs for Actionable Mutations

Dr Edward Kim, a principal investigator in ASCO's TAPUR study, describes the trial's unique approach to evaluating the efficacy of targeted cancer therapies prescribed off-label.